EU Cardiovascular Health Plan – FH Europe Foundation feedback submitted: now we need your endorsement!
We are pleased to share that FH Europe Foundation, in consultation with our Community and Partners, has officially submitted its feedback to the European Commission’s consultation on the EU Cardiovascular Health Plan 🫀.
This marks an important milestone in ensuring that inherited lipid disorders—familial hypercholesterolaemia (FH), homozygous FH, elevated Lp(a), and familial chylomicronaemia syndrome (FCS)—are fully recognised as major cardiovascular disease (CVD) risk factors within EU-level health policy.
In our submission, we are calling for a CVH Plan that will:
✅ Embed familial lipid disorders into the EU Cardiovascular Health Plan
✅ Make systematic early lipid screening and detection a cornerstone of prevention
✅ Ensure equity in access to testing and personalised management and treatment pathways
✅ Ensure patient and citizen involvement
✅ Support Member States with EU-level action
✅ Invest in health innovation and data use
Now, we need your help to amplify this message!
By endorsing our submission, you can add weight to the patient voice and strengthen the call for policies that prioritise early detection and prevention.
⏰ The deadline is 15 September 2025.
Please take a few minutes to endorse our submission today.
How to endorse:
-
Access the EU Login Page.
-
Click “Create an account” and complete your details.
-
Confirm your email (link valid for 24h) and set a secure password.
-
Log in to the platform and participate in the EU CVH consultation process.
Watch the video instructions:
Every endorsement matters.
Together, we can secure the visibility and priority that inherited lipid disorders deserve in the EU Cardiovascular Health Plan.
Thank you for your continued engagement and support.
With kind regards,
FH Europe Foundation
Magdalena Daccord
Chief Executive Officer
FH Europe Foundation
ABOUT THE CONSULTATION
The European Commission has launched a public consultation on the EU Cardiovascular Health Plan, a significant milestone in EU health policy and a long-awaited opportunity to influence strategies for cardiovascular disease health.
This consultation represents a unique chance to ensure that inherited lipid disorders, familial hypercholesterolaemia (FH), homozygous FH, elevated Lp(a), and familial chylomicronaemia syndrome (FCS), are fully recognised as major CVD risk factors within EU-level policy, alongside clear recommendations for early lipid screening, detection, and personalised management. Learn more.
